New Companies
Filter News
Found 3,925 articles
-
The precision medicine company is developing mutant selective and isoform-specific drugs in non-conventional ways for well-known targets in the oncology and autoimmune spaces.
-
Money on the Move: November 17 – 23
11/24/2021
Plenty to be thankful for this week for these biopharma companies, especially with the influx of cash. -
Vaccibody has changed its name to Nykode Therapeutics. “Nykode” means “new code,” which plays on the potential of the company to generate novel codes and innovative patient therapies.
-
Avilar Therapeutics officially joined the game with $60 million in seed financing from RA Capital Management.
-
Chroma Medicine debuted Wednesday morning with $125 million in seed and Series A funding.
-
Illumina and Sequoia Capital China Select First Startups to join Genomics Incubator in China
11/17/2021
Illumina, Inc., and Sequoia Capital China, a leading investment firm, jointly announced the selection of the first two startup companies joining the Sequoia Capital China Intelligent Healthcare Genomics Incubator, Powered by Illumina.
-
Johnson & Johnson Announces Plans to Accelerate Innovation, Serve Patients and Consumers, and Unlock Value through Intent to Separate Consumer Health Business
11/12/2021
Johnson & Johnson announced its intent to separate the Company's Consumer Health business, creating a new publicly traded company.
-
Eric Ostertag, CEO of Poseida Therapeutics, believes the future of CAR-T programs is with allogeneic approaches and not autologous.
-
Money on the Move: November 3 – 9
11/10/2021
Investors are lighting up the season already for these biotechs, now flush with cash to spend. Here's who snagged funding this week. -
Alltrna, based in Cambridge, Mass. near its cousin Moderna, debuts as the first platform transfer RNA (tRNA) company.
-
DeepCure announced the closing of its $40 million Series A financing round. The round, led by Morningside Ventures, brings the company’s total amount raised to $47 million since it was founded in 2018.
-
Biotech Startup Mekonos raises oversubscribed $25 million round to overcome pharma industry's cell & gene therapy delivery hurdles
11/9/2021
The new capital will accelerate the development of Mekonos' System on a Chip (SoC), expand commercial partnerships, and support talent acquisition
-
Ligand Pursuing Plans for OmniAb to Become a Standalone Public Company
11/9/2021
Ligand Pharmaceuticals Incorporated announced it is pursuing plans to split Ligand into two separate, publicly traded companies with one featuring the OmniAb business, and the other featuring Ligand’s existing collection of core royalties and the technologies, pipeline and contracts associated with the Pelican protein expression platform and the Captisol business.
-
The $80 million infusions from ATP will advance Marengo’s lead candidate, STAR0602, which aims to treat advanced and metastatic solid tumors.
-
Marengo Therapeutics Launches with $80M from ATP, Appoints CEO Zhen Su, MD, to Deliver Breakthrough Cancer Treatments Using Its Selective T Cell Activation Repertoire (STAR) Platform
11/8/2021
ATP, a leader in life sciences venture capital, today announced the launch of Marengo Therapeutics, Inc.
-
bluebird bio has completed the spin-off of its oncology programs into the new business entity, 2seventy bio, Inc, which will begin trading on the Nasdaq this morning under the ticker symbol “TSVT.”
-
Isomorphic Laboratories has expressed plans to foray into drug discovery and development by tapping into the technology of its sister company DeepMind.
-
Clade Therapeutics will use its funds to further its research and development on cancer treatments, while GRO Biosciences will focus on chronic diseases.
-
Novartis has forged a collaboration with U.K.-startup Dunad Therapeutics to develop next-generation targeted protein-degradation therapies in a deal valued at up to $1.3 billion.
-
Vernalis Research - a Fully Owned Subsidiary of HitGen Inc - and Hannibal Innovation Announce the Creation of Dania Therapeutics ApS
11/1/2021
Vernalis Research, a fully owned subsidiary of HitGen Inc., and Hannibal Innovation ApS are pleased to announce the creation of Dania Therapeutics ApS to discover small molecules inhibitors against new undisclosed oncology targets.